Incremental value of intact fibroblast growth factor 23 to natriuretic peptides for long-term risk estimation of heart failure patients.
Fibroblast growth factor 23 (FGF-23), a key hormone for the regulation of the phosphorus homeostasis, has also several direct effects on cardiac function. In heart failure (HF), the increase of FGF-23 participates to cardiac hypertrophy and remodeling. Measurement of the intact, biologically active hormone is now available. We determined intact FGF-23 in HF patients with reduced ejection fraction and assess its prognosis value for cardiovascular death over a long-term follow-up. We observed that intact FGF-23 is an independent predictor of cardiovascular death in HF patients and provides added... Mehr ...
| Verfasser: | |
|---|---|
| Dokumenttyp: | Artikel |
| Erscheinungsdatum: | 2018 |
| Schlagwörter: | Aged / Belgium / Biomarkers / Cardiomyopathy / Dilated / Female / Fibroblast Growth Factor-23 / Fibroblast Growth Factors / Follow-Up Studies / Heart / Heart Failure / Humans / Immunoassay / Male / Middle Aged / Myocardial Ischemia / Natriuretic Peptide / Brain / Peptide Fragments / Practice Guidelines as Topic / Prognosis / Risk Assessment / Severity of Illness Index / Stroke Volume / Diabetes / FGF-23 / Iron metabolism / NT-proBNP / Outcomes |
| Sprache: | Englisch |
| Permalink: | https://search.fid-benelux.de/Record/base-28928855 |
| Datenquelle: | BASE; Originalkatalog |
| Powered By: | BASE |
| Link(s) : | http://hdl.handle.net/2078.1/263932 |
Fibroblast growth factor 23 (FGF-23), a key hormone for the regulation of the phosphorus homeostasis, has also several direct effects on cardiac function. In heart failure (HF), the increase of FGF-23 participates to cardiac hypertrophy and remodeling. Measurement of the intact, biologically active hormone is now available. We determined intact FGF-23 in HF patients with reduced ejection fraction and assess its prognosis value for cardiovascular death over a long-term follow-up. We observed that intact FGF-23 is an independent predictor of cardiovascular death in HF patients and provides added value to the standard of care, natriuretic peptide, for risk estimation.